Baudax Bio Says Poised To Initiate TI-168 Clinical Development Following Recent Shareholder Approval Of Corporate Actions Related To TeraImmune Acquisition
Baudax Bio Says Poised To Initiate TI-168 Clinical Development Following Recent Shareholder Approval Of Corporate Actions Related To TeraImmune Acquisition
Baudax Bio 表示，在股東最近批准與收購 TeraimMune 相關的公司行動後，準備啓動 TI-168 臨床開發
Baudax Bio Says Poised To Initiate TI-168 Clinical Development Following Recent Shareholder Approval Of Corporate Actions Related To TeraImmune Acquisition
Baudax Bio 表示，在股東最近批准與收購 TeraimMune 相關的公司行動後，準備啓動 TI-168 臨床開發
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。